Michael Demurjian Net Worth

The estimated Net Worth of Michael Demurjian is at least $11.5 Million dollars as of 6 September 2022. Michael Demurjian owns over 160,000 units of Tyme Technologies Inc stock worth over $6,959,142 and over the last 7 years Michael sold TYME stock worth over $4,514,282.

Michael Demurjian TYME stock SEC Form 4 insiders trading

Michael has made over 157 trades of the Tyme Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Michael sold 160,000 units of TYME stock worth $40,000 on 6 September 2022.

The largest trade Michael's ever made was selling 160,000 units of Tyme Technologies Inc stock on 6 September 2022 worth over $40,000. On average, Michael trades about 27,271 units every 11 days since 2017. As of 6 September 2022 Michael still owns at least 22,448,846 units of Tyme Technologies Inc stock.

You can see the complete history of Michael Demurjian stock trades at the bottom of the page.

What's Michael Demurjian's mailing address?

Michael's mailing address filed with the SEC is 157 BROAD STREET, SUITE 304, RED BANK, NJ, 07701.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, and Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Complete history of Michael Demurjian stock trades at Tyme Technologies Inc

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer